Abstract: 2-primary amino-4-secondary amino-quinoline derivatives, their manufacture, pharmaceutical compositions comprising them and their use as medicaments are disclosed. The compounds are useful as a medicament in treating and/or decreasing the severity and/or progression and/or preventing fibrosis and/or related diseases, or for use as a medicament in treating, decreasing the severity and/or progression of and/or preventing autophagy and/or related diseases, for inhibiting autophagy flux, and for inhibiting cathepsins B (CTSB), L (CTSL) and/or D (CTSD) and/or related diseases.
Abstract: The present invention relates to novel 2-primary amino-4-secondary amino-quinoline derivatives, their manufacture, pharmaceutical compositions comprising them and their use as medicaments. The active compounds of the present invention are useful for the treatment and prevention of proliferative neoplastic and non-neoplastic diseases.
Type:
Grant
Filed:
October 26, 2015
Date of Patent:
July 28, 2020
Assignee:
GENOSCIENCE PHARMA
Inventors:
Firas Bassissi, Antoine Beret, Sonia Brun, Jérôme Courcambeck, Clarisse Dubray, Gregory Nicolas, Philippe Halfon
Abstract: This application discloses compounds according to generic Formula I: wherein all variables are defined as described herein which exhibit strong inhibition effects on various cancer cell lines. The compounds disclosed herein are useful for the treatment of proliferative diseases, including neoplastic diseases such as cancer and non-neoplastic disorders such as rheumatoid arthritis. Also disclosed are pharmaceutical compositions containing compounds of Formula I and at least one carrier, diluent or excipient and optionally one or more additional therapeutically active agents, including anticancer agents. This application also discloses methods for treating a proliferative disease, including neoplastic diseases such as cancer and non-neoplastic disorders such as rheumatoid arthritis.
Type:
Grant
Filed:
May 4, 2017
Date of Patent:
March 3, 2020
Assignee:
GENOSCIENCE PHARMA
Inventors:
Sonia Brun, Antoine Beret, Firas Bassissi, Philippe Halfon, Jérôme Courcambeck
Abstract: This application discloses compounds according to generic Formula I: wherein all variables are defined as described herein which exhibit strong inhibition effects on various cancer cell lines. The compounds disclosed herein are useful for the treatment of proliferative diseases, including neoplastic diseases such as cancer and non-neoplastic disorders such as rheumatoid arthritis. Also disclosed are pharmaceutical compositions containing compounds of Formula I and at least one carrier, diluent or excipient and optionally one or more additional therapeutically active agents, including anticancer agents. This application also discloses methods for treating a proliferative disease, including neoplastic diseases such as cancer and non-neoplastic disorders such as rheumatoid arthritis.
Type:
Application
Filed:
May 4, 2017
Publication date:
May 16, 2019
Applicant:
GENOSCIENCE PHARMA
Inventors:
Sonia BRUN, Antoine BERET, Firas BASSISSI, Philippe HALFON, Jérôme COURCAMBECK
Abstract: The invention provides quinoline derivatives, their manufacture, pharmaceutical compositions containing them, and their use as medicaments. The active compounds of the present invention are useful for the treatment of proliferative neoplastic and non-neoplastic diseases.
Type:
Grant
Filed:
March 13, 2014
Date of Patent:
January 15, 2019
Assignee:
GENOSCIENCE PHARMA
Inventors:
Jerome Courcambeck, Philippe Halfon, Firas Bassissi, Sonia Brun, Gregory Nicolas, Antoine Beret, Serge Petit, Claire Camus, Jean Pierre Nallet
Abstract: The present invention is directed to compounds, compositions and methods for treating or preventing viral infections, in particular, HCV in human patients or other animal hosts.
Type:
Application
Filed:
October 28, 2011
Publication date:
May 24, 2012
Applicants:
GENOSCIENCE, RFS Pharma, LLC
Inventors:
Jerome Courcambeck, Philippe Halfon, Mourad Bouzidi, Steven J. Coats, Richard Anthony Whitaker
Abstract: The present invention relates to novel hepatitis C virus (“HCV”) protease inhibitors or other flavivirus protease inhibitors having the general structure (I) or (II), pharmaceutical compositions containing one or more such inhibitors, methods for preparing such inhibitors, uses of these compounds to treat hepatitis C and related disorders together with their use for their activity towards NS3 serine protease, intermediary compounds for the method of preparation of said compounds and screening methods. The invention specifically discloses novel chemical compounds as inhibitors of the HCV serine protease.
Type:
Application
Filed:
October 9, 2003
Publication date:
June 29, 2006
Applicant:
GENOSCIENCE
Inventors:
Philippe Halfon, Chalom Sayada, Jean-Marc Feryn, Regis Perbost, Frederic Garzino, Michel Camplo, Jerome Courcambeck, Gerard Pepe